EMAIL THIS PAGE TO A FRIEND

PloS one

Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice.


PMID 25369030

Abstract

Recent advances in cancer biology have revealed that many malignancies possess a hierarchal system, and leukemic stem cells (LSC) or leukemia-initiating cells (LIC) appear to be obligatory for disease progression. Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by the formation of a PML-RARα fusion protein, leads to the accumulation of abnormal promyelocytes. In order to understand the precise mechanisms involved in human APL leukemogenesis, we established a humanized in vivo APL model involving retroviral transduction of PML-RARA into CD34(+) hematopoietic cells from human cord blood and transplantation of these cells into immunodeficient mice. The leukemia well recapitulated human APL, consisting of leukemic cells with abundant azurophilic abnormal granules in the cytoplasm, which expressed CD13, CD33 and CD117, but not HLA-DR and CD34, were clustered in the same category as human APL samples in the gene expression analysis, and demonstrated sensitivity to ATRA. As seen in human APL, the induced APL cells showed a low transplantation efficiency in the secondary recipients, which was also exhibited in the transplantations that were carried out using the sorted CD34- fraction. In order to analyze the mechanisms underlying APL initiation and development, fractionated human cord blood was transduced with PML-RARA. Common myeloid progenitors (CMP) from CD34(+)/CD38(+) cells developed APL. These findings demonstrate that CMP are a target fraction for PML-RARA in APL, whereas the resultant CD34(-) APL cells may share the ability to maintain the tumor.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1406022
Anti-IL3RA antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA003539
Anti-IL3RA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA008312 Anti-PML antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV33048
Anti-PML antibody produced in rabbit, affinity isolated antibody
SAB2101834
Anti-PML antibody produced in rabbit, affinity isolated antibody
SAB2104491
Anti-PML antibody produced in rabbit, affinity isolated antibody
P6746
Monoclonal Anti-PML antibody produced in mouse, clone PML-97, purified immunoglobulin, buffered aqueous solution
WH0005371M2
Monoclonal Anti-PML antibody produced in mouse, clone 1D12, purified immunoglobulin, buffered aqueous solution
SAB1404223
Monoclonal Anti-PML antibody produced in mouse, clone 2B10, purified immunoglobulin, buffered aqueous solution
PLA0172
Rabbit anti-PML Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
PHR1187
Tretinoin, Pharmaceutical Secondary Standard; Certified Reference Material
C20H28O2
1674004
Tretinoin, United States Pharmacopeia (USP) Reference Standard
C20H28O2
T1850000
Tretinoin, European Pharmacopoeia (EP) Reference Standard
C20H28O2